Individualized dosing with KYNMOBI™ (apomorphine HCl)1

5 strengths available to help find your patient’s optimal dose

  • KYNMOBI is available in 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg dose strengths
    • The maximum single dose of KYNMOBI is 30 mg
  • KYNMOBI should be taken no more than 5 times a day
  • Doses should be separated by at least 2 hours
    • If a single dose of KYNMOBI is ineffective for a particular OFF episode, a second dose should not be taken for that OFF episode. The efficacy or safety of administering a second dose for a single OFF episode has not been studied
  • An antiemetic (eg, trimethobenzamide 300 mg) is recommended, beginning 3 days prior to the initial dose of KYNMOBI but generally no longer than 2 months after the initial dose, given the incidence of nausea and vomiting
KYNMOBI is available in 5 dose strengths: 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg.
KYNMOBI is available in 5 dose strengths: 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg.
KYNMOBI can be used for any OFF episode at any time of day, up to 5 times a day, regardless of when other PD medications are taken1,2

How to Titrate to the optimal Dose1

Titration should be done under the supervision of a health care provider

Start with the 10 mg dose under the supervision of a health care provider. If full ON is achieved, prescribe 10 mg. If dose was tolerated but ON was not achieved, increase to next dose strength at next OFF. Doses should be separated by at least 2 hours. Increase by 5 mg and reassess response. Continue titrating until effective and tolerable dose is achieved. Among patients who successfully titrated to an effective and tolerable dose, most were able to do so in the first 3 titrated doses.
Start with the 10 mg dose under the supervision of a health care provider. If full ON is achieved, prescribe 10 mg. If dose was tolerated but ON was not achieved, increase to next dose strength at next OFF. Doses should be separated by at least 2 hours. Increase by 5 mg and reassess response. Continue titrating until effective and tolerable dose is achieved. Among patients who successfully titrated to an effective and tolerable dose, most were able to do so in the first 3 titrated doses.
Among patients who successfully titrated to an effective and tolerable dose, most were able to do so in the first three titrated doses3†

*In the KYNMOBI clinical trial, a patient self-rated full ON response was defined as a global impression of whether they were experiencing a period of time where the medication provided benefit with regard to mobility, stiffness, and slowness, and performing daily activities. Individual component improvements were assessed in clinic but not recorded.4

32/141 patients discontinued during the titration phase of the trial.2

Learn about the Dosing Observation
and Monitoring Program

Watch a short video to see how KYNMOBI is administered

Find out how to
prescribe KYNMOBI

References: 1. Kynmobi. Prescribing information. Sunovion Pharmaceuticals Inc; May 2020. 2. Olanow CW, Factor SA, Espay AJ, et al; for the CTH-300 Study Investigators. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomized, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19[2]:135-144. 3. Hui JS, Fox SH, Neeson W, et al. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes. Parkinsonism and Related Disorders. 2020;79:110-116. 4. CTH-300 study. Data on file. Sunovion Pharmaceuticals Inc.

Top

Thank you for registering at KYNMOBI!

We look forward to telling you more about KYNMOBI, a new medication to treat OFF episodes associated with Parkinson's disease, as it becomes available.

You have been successfully unsubscribed.

Please allow 7-10 days to process your request.